» Articles » PMID: 35960668

Sustained Research Fund and Dedicated Research Center to Prepare for the Next Pandemic

Overview
Journal Precis Clin Med
Specialty General Medicine
Date 2022 Aug 12
PMID 35960668
Authors
Affiliations
Soon will be listed here.
Abstract

The current COVID-19 pandemic caused by the SARS-CoV-2 virus is imposing a great threat to human lives and international panic the like of which has not been seen since WWII, resulting in financial crisis, disturbance to daily life, transportation shutdown, industry disruption, and country/city lockdown in every corner of the globe. The inability to effectively contain the virus indicates that our investment and attention to research, prevention, and development of treatment for this type of deadly virus are insufficient, considering that it has been 18 years since outbreak of the "brother" coronavirus, SARS-CoV. The biggest lesson learned from acrimonious past experiences is that humans quickly forget and do not continue to support related research when a pandemic has passed. This is a wake-up call for governments, industry, and private foundations to work together and to take extraordinary measures to sustain research support and establish comprehensive research centers. Only this level of response may give us hope to prepare for the future and adequately deal with the next potential pandemic caused by emerging devastating viral infections.

Citing Articles

Control and prevention of infectious diseases from a One Health perspective.

Ellwanger J, da Veiga A, Kaminski V, Valverde-Villegas J, Freitas A, Chies J Genet Mol Biol. 2021; 44(1 Suppl 1):e20200256.

PMID: 33533395 PMC: 7856630. DOI: 10.1590/1678-4685-GMB-2020-0256.


Calling for a united action to defeat COVID-19.

Overby M, Pu Q, Wei X, Wu M Precis Clin Med. 2020; 3(3):235-239.

PMID: 33214930 PMC: 7454840. DOI: 10.1093/pcmedi/pbaa027.


Medical research during the COVID-19 pandemic.

AlNaamani K, AlSinani S, Barkun A World J Clin Cases. 2020; 8(15):3156-3163.

PMID: 32874970 PMC: 7441262. DOI: 10.12998/wjcc.v8.i15.3156.

References
1.
Lin J, Zhang J, Su N, Xu J, Wang N, Chen J . Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine. Antivir Ther. 2007; 12(7):1107-13. View

2.
Martin J, Louder M, Holman L, Gordon I, Enama M, Larkin B . A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine. 2008; 26(50):6338-43. PMC: 2612543. DOI: 10.1016/j.vaccine.2008.09.026. View

3.
Wang Q, Zhang L, Kuwahara K, Li L, Liu Z, Li T . Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates. ACS Infect Dis. 2016; 2(5):361-76. PMC: 7075522. DOI: 10.1021/acsinfecdis.6b00006. View

4.
Holshue M, DeBolt C, Lindquist S, Lofy K, Wiesman J, Bruce H . First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020; 382(10):929-936. PMC: 7092802. DOI: 10.1056/NEJMoa2001191. View